DDInter40 DDInter350
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Chlorambucil
Alefacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) downregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Chlorambucil
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) upregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Chlorambucil
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Ustekinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Chlorambucil
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) causes {v} (Side Effect) Hyperuricaemia
Hyperuricaemia {u} (Side Effect) is caused by {v} (Compound) Chlorambucil
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Chlorambucil (Compound)
Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) downregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Chlorambucil (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Chlorambucil (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Chlorambucil (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) causes Hyperuricaemia (Side Effect) and Hyperuricaemia (Side Effect) is caused by Chlorambucil (Compound)